StockNews.com upgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a hold rating to a buy rating in a research note ...

StockNews.com downgraded shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning. Separately, Scotiabank assumed ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. Innoviva’s other innovative healthcare assets include infectious disease and ...

Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...

GSK also manufactures Advair, Anoro Ellipta and Arnuity Ellipta for asthma. It also manufactures Augmentin, an antibiotic used to treat various bacterial infections. GSK’s exit and change of model ...

Some GSK also manufactures Advair, Anoro Ellipta and Arnuity Ellipta for asthma. Their exit and change of model have put pressure on patients who now spend more than 100 per cent more than the usual ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as ...